Genetic Re-programming of Stem Cells to Fight Cancer

• Post author:
• Post published:June 4, 2025
• Post category:

Science has made great progress in the treatment of certain cancers with targeted and combination therapies, yet prolonged remissions or cures are rare because most cancer therapies only inhibit cell…

Continue ReadingGenetic Re-programming of Stem Cells to Fight Cancer

Evaluation of Safety and Preliminary Efficacy of Escalating Doses of GRNOPC1 in Subacute Spinal Cord Injury

• Post author:
• Post published:June 4, 2025
• Post category:

The proposed project is designed to assess the safety and preliminary activity of escalating doses of human embryonic stem cell (hESC) derived oligodendrocyte progenitor cells for treatment of spinal cord…

Continue ReadingEvaluation of Safety and Preliminary Efficacy of Escalating Doses of GRNOPC1 in Subacute Spinal Cord Injury

TRX103 for prevention of GvHD in patients receiving HLA mismatched HSCT for the treatment of hematologic malignancies

• Post author:
• Post published:June 3, 2025
• Post category:

Continue ReadingTRX103 for prevention of GvHD in patients receiving HLA mismatched HSCT for the treatment of hematologic malignancies

Optogenetic Gene Therapy for Treatment of Retinitis Pigmentosa

• Post author:
• Post published:June 3, 2025
• Post category:

Continue ReadingOptogenetic Gene Therapy for Treatment of Retinitis Pigmentosa

Autologous BCMA CAR-T Cells for the Treatment of Relapsed Refractory Light Chain Amyloidosis

• Post author:
• Post published:June 3, 2025
• Post category:

Continue ReadingAutologous BCMA CAR-T Cells for the Treatment of Relapsed Refractory Light Chain Amyloidosis

Phase 1b Study of TN-401 in Adults with PKP2 Mutation-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

• Post author:
• Post published:June 3, 2025
• Post category:

Continue ReadingPhase 1b Study of TN-401 in Adults with PKP2 Mutation-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

A Phase I/IIa Study to Evaluate the Efficacy of Toca 511/Toca FC with Standard of Care Therapy in Newly Diagnosed High Grade Glioma

• Post author:
• Post published:June 3, 2025
• Post category:

Continue ReadingA Phase I/IIa Study to Evaluate the Efficacy of Toca 511/Toca FC with Standard of Care Therapy in Newly Diagnosed High Grade Glioma

A PHASE 1B STUDY EVALUATING THE SAFETY AND EFFICACY OF AN ALLOGENEIC CELL THERAPY IN SUBJECTS WITH CLEAR CELL RENAL CELL CARCINOMA (ccRCC)

• Post author:
• Post published:June 3, 2025
• Post category:

Continue ReadingA PHASE 1B STUDY EVALUATING THE SAFETY AND EFFICACY OF AN ALLOGENEIC CELL THERAPY IN SUBJECTS WITH CLEAR CELL RENAL CELL CARCINOMA (ccRCC)

Selective, Off-the-Shelf Logic Gated CAR NK Cell Therapy Targeting CD33 and/or FLT3 Expressing Hematologic Malignancies

• Post author:
• Post published:June 3, 2025
• Post category:

Continue ReadingSelective, Off-the-Shelf Logic Gated CAR NK Cell Therapy Targeting CD33 and/or FLT3 Expressing Hematologic Malignancies

Phase 1 Study of Autologous E-SYNC T Cells in Adult Participants with EGFRvIII+ Glioblastoma

• Post author:
• Post published:June 3, 2025
• Post category:

Continue ReadingPhase 1 Study of Autologous E-SYNC T Cells in Adult Participants with EGFRvIII+ Glioblastoma